MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults
Status and phase
Completed
Phase 4
Conditions
Asthma
Treatments
Drug: Conventional Best Asthma Therapy
Drug: Budesonide/Formoterol Turbuhaler
Details and patient eligibility
About
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.
Sex
All
Ages
12+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Diagnosis of asthma >= 3 months
- Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1
Exclusion criteria
- Smoking history > 10 pack-years
- Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
- Any significant disease or disorder that may jeopardize the safety of the patient.
Additional inclusion and exclusion criteria will be evaluated by the investigator.
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
None (Open label)
Trial contacts and locations
181
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems